Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Trial

AIMS: For patients with depression, the likelihood of remission decreases with each subsequent treatment failure. Per European Medicines Agency guidance, treatment resistant depression (TRD) is defined as nonresponse to ≥2 consecutive treatments at adequate dosage and duration in the current depress...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, A.H., Cubała, W.J., Nielsen, R.E., Popova, A., Ito, T., Mulhern-Haughey, S., Pirotte, N., Rive, B., Thilakarathne, P., Usankova, I., Godinov, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345580/
http://dx.doi.org/10.1192/bjo.2023.245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345580/
http://dx.doi.org/10.1192/bjo.2023.245

Ejemplares similares